Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 2Melanoma 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Solid Tumors 1Solid Tumor 1Small Cell Lung Carcinoma 1Primary Myelofibrosis 1PD-L1 Positive Mutation Tumor 1Metastatic Solid Tumors 1Mesothelioma 1Malignant Solid Tumour 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

Vorinostat 2pembrolizumab 1nintedanib 1dactolisib 1avelumab 1Vinorelbine 1Sunitinib 1Oxaliplatin 1Levoleucovorin 1Leucovorin 1Hydroxychloroquine 1Folfox protocol 1Fluorouracil 1Dasatinib 1DOXO-EMCH 1Cetuximab 1Bevacizumab 1BN 80927 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant Solid Tumour × avelumab × Other solid neoplasm × Clear all
NCT02923466 2022-04-27

Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors

Vyriad, Inc.

Phase 1 Completed
76 enrolled
Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡